|
1
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al: Tracking the evolution of non-small-cell lung
cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwartz L, Supuran CT and Alfarouk KO:
The Warburg effect and the hallmarks of cancer. Anticancer Agents
Med Chem. 17:164–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ngo DC, Ververis K, Tortorella SM and
Karagiannis TC: Introduction to the molecular basis of cancer
metabolism and the Warburg effect. Mol Biol Rep. 42:819–823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Allen AE and Locasale JW: Glucose
metabolism in cancer: The saga of pyruvate kinase continues. Cancer
Cell. 33:337–339. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Israelsen WJ and Vander Heiden MG:
Pyruvate kinase: Function, regulation and role in cancer. Semin
Cell Dev Biol. 43:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Chen M, Gao S, Yuan J, Zhu Z and Zou
X: LY294002 inhibits the Warburg effect in gastric cancer cells by
downregulating pyruvate kinase M2. Oncol Lett. 15:4358–4364.
2018.PubMed/NCBI
|
|
8
|
Li J, Cheng D, Zhu M, Yu H, Pan Z, Liu L,
Geng Q, Pan H, Yan M and Yao M: OTUB2 stabilizes U2AF2 to promote
the Warburg effect and tumorigenesis via the AKT/mTOR signaling
pathway in non-small cell lung cancer. Theranostics. 9:179–195.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong
SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes
cell glycolysis, growth, migration, and invasion in non-small cell
lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol.
8:222015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao W, Li W, Dai W, Huang N and Qiu J:
LINK-A promotes cell proliferation through the regulation of
aerobic glycolysis in non-small-cell lung cancer. Onco Targets
Ther. 11:6071–6080. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen H, Zhang M, Zhang W, Li Y, Zhu J,
Zhang X, Zhao L, Zhu S and Chen B: Downregulation of BarH-like
homeobox 2 promotes cell proliferation, migration and aerobic
glycolysis through Wnt/β-catenin signaling, and predicts a poor
prognosis in non-small cell lung carcinoma. Thorac Cancer.
9:390–399. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu T and Lu YR: BCYRN1, a c-MYC-activated
long non-coding RNA, regulates cell metastasis of non-small-cell
lung cancer. Cancer Cell Int. 15:362015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Zheng L, Jiang A, Mo Y and Gong Q:
Identification of the biological affection of long noncoding RNA
BC200 in Alzheimer's disease. Neuroreport. 29:1061–1067. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Booy EP, McRae EK, Koul A, Lin F and
McKenna SA: The long non-coding RNA BC200 (BCYRN1) is critical for
cancer cell survival and proliferation. Mol Cancer. 16:1092017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th Edition of the AJCC Cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lim SO, Li CW, Xia W, Lee HH, Chang SS,
Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, et al: EGFR signaling
enhances aerobic glycolysis in triple-negative breast cancer cells
to promote tumor growth and immune escape. Cancer Res.
76:1284–1296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kong XZ, Hu SS, Sun Z, Zuo LH, Kang J, Zhu
ZF, Tian X and Zhang XJ: Regulation of aerobic glycolysis by long
non-coding RNAs in cancer. Biochem Biophys Res Commun. 479:28–32.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goncalves MD and Cantley LC: A glycolysis
outsider steps into the cancer spotlight. Cell Metab. 28:3–4. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen R, Zhu S, Fan XG, Wang H, Lotze MT,
Zeh HJ III, Billiar TR, Kang R and Tang D: High mobility group
protein B1 controls liver cancer initiation through yes-associated
protein-dependent aerobic glycolysis. Hepatology. 67:1823–1841.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Lu JH, Wu QN, Jin Y, Wang DS, Chen
YX, Liu J, Luo XJ, Meng Q, Pu HY, et al: LncRNA LINRIS stabilizes
IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer.
Mol Cancer. 18:1742019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li T, Sun X and Jiang X: UCA1 involved in
the metformin-regulated bladder cancer cell proliferation and
glycolysis. Tumour Biol. 39:10104283177108232017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang P, Cao L, Fan P, Mei Y and Wu M:
LncRNA-MIF, a c-Myc-activated long non-coding RNA, suppresses
glycolysis by promoting Fbxw7-mediated c-Myc degradation. EMBO Rep.
17:1204–1220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song J, Wu X, Liu F, Li M, Sun Y, Wang Y,
Wang C, Zhu K, Jia X, Wang B and Ma X: Long non-coding RNA PVT1
promotes glycolysis and tumor progression by regulating miR-497/HK2
axis in osteosarcoma. Biochem Biophys Res Commun. 490:217–224.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peng J, Hou F, Feng J, Xu SX and Men XY:
Long non-coding RNA BCYRN1 promotes the proliferation and
metastasis of cervical cancer via targeting microRNA-138 in vitro
and in vivo. Oncol Lett. 15:5809–5818. 2018.PubMed/NCBI
|
|
26
|
Gu L, Lu L, Zhou D and Liu Z: Long
noncoding RNA BCYRN1 promotes the proliferation of colorectal
cancer cells via Up-regulating NPR3 expression. Cell Physiol
Biochem. 48:2337–2349. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren H, Yang X, Yang Y, Zhang X, Zhao R,
Wei R, Zhang X and Zhang Y: Upregulation of LncRNA BCYRN1 promotes
tumor progression and enhances EpCAM expression in gastric
carcinoma. Oncotarget. 9:4851–4861. 2017.PubMed/NCBI
|
|
28
|
Zhang XY, Tang XY, Ma LJ, Guo YL, Li XS,
Zhao LM, Tian CJ, Cheng DJ, Chen ZC and Zhang LX: Schisandrin B
down-regulated lncRNA BCYRN1 expression of airway smooth muscle
cells by improving miR-150 expression to inhibit the proliferation
and migration of ASMC in asthmatic rats. Cell Prolif.
50:e123822017. View Article : Google Scholar
|
|
29
|
Jin L, Li Y, Liu J, Yang S, Gui Y, Mao X,
Nie G and Lai Y: Tumor suppressor miR-149-5p is associated with
cellular migration, proliferation and apoptosis in renal cell
carcinoma. Mol Med Rep. 13:5386–5392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G,
Yang J, Xia L, Wang R, Cai X, Hu H, et al: MicroRNA-149 inhibits
proliferation and cell cycle progression through the targeting of
ZBTB2 in human gastric cancer. PLoS One. 7:e416932012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang F, Ma YL, Zhang P, Shen TY, Shi CZ,
Yang YZ, Moyer MP, Zhang HZ, Chen HQ, Liang Y and Qin HL: SP1
mediates the link between methylation of the tumour suppressor
miR-149 and outcome in colorectal cancer. J Pathol. 229:12–24.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao L, Liu L, Dong Z and Xiong J: miR-149
suppresses human non-small cell lung cancer growth and metastasis
by inhibiting the FOXM1/cyclin D1/MMP2 axis. Oncol Rep.
38:3522–3530. 2017.PubMed/NCBI
|
|
33
|
Qian B, Zhao L, Wang X, Xu J, Teng F, Gao
L and Shen R: RETRACTED: miR-149 regulates the proliferation and
apoptosis of cervical cancer cells by targeting GIT1. Biomed
Pharmacother. 105:1106–1116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dayton TL, Jacks T and Vander Heiden MG:
PKM2, cancer metabolism, and the road ahead. EMBO Rep.
17:1721–1730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L
and Jiang F: PKM2 and cancer: The function of PKM2 beyond
glycolysis. Oncol Lett. 11:1980–1986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Papadaki C, Sfakianaki M, Lagoudaki E,
Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A,
Koutsopoulos A, Mavroudis D, et al: PKM2 as a biomarker for
chemosensitivity to front-line platinum-based chemotherapy in
patients with metastatic non-small-cell lung cancer. Br J Cancer.
111:1757–1764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He J, Xie G, Tong J, Peng Y, Huang H, Li
J, Wang N and Liang H: Overexpression of microRNA-122 re-sensitizes
5-FU-resistant colon cancer cells to 5-FU through the inhibition of
PKM2 in vitro and in vivo. Cell Biochem Biophys. 70:1343–1350.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang HJ, Hsieh YJ, Cheng WC, Lin CP, Lin
YS, Yang SF, Chen CC, Izumiya Y, Yu JS, Kung HJ and Wang WC: JMJD5
regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated
glucose metabolism. Proc Natl Acad Sci USA. 111:279–284. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luan W, Wang Y, Chen X, Shi Y, Wang J,
Zhang J, Qian J, Li R, Tao T, Wei W, et al: PKM2 promotes glucose
metabolism and cell growth in gliomas through a mechanism involving
a let-7a/c-Myc/hnRNPA1 feedback loop. Oncotarget. 6:13006–13018.
2015. View Article : Google Scholar : PubMed/NCBI
|
